Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand
- Fisher & Paykel Healthcare Sleep Laboratory
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18+
- Patients diagnosed with obesity hypoventilation syndrome (OHS) and/or obstructive sleep apnea (OSA) by a practicing sleep or respiratory physician, requiring positive airway pressure (PAP) therapy
Exclusion Criteria:
- Recent cardiac or respiratory arrest
- Gastro intestinal bleeding, ileus or recent gastrointestinal surgery
- Coma, decreased level of consciousness or agitation
- Anatomical or subjective difficulty with airway access e.g. facial surgery, trauma, vomiting upper airway obstruction
- Cerebrospinal fluid leak, abnormalities of the cribiform plate or prior history of head trauma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Positive airway pressure (PAP) device
Fisher & Paykel Healthcare PAP Device.
Participants will sleep overnight using themodified positive airway pressure device.
Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
|
The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apnea hypopnea index (AHI)
Time Frame: 8 hours
|
The number of apnea and hypopneas will be measured
|
8 hours
|
|
Peripheral blood oxygen level (SpO2)
Time Frame: 8 hours
|
Peripheral blood oxygen level will be measured
|
8 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Overnutrition
- Nutrition Disorders
- Signs and Symptoms, Respiratory
- Respiratory Insufficiency
- Obesity
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Hypoventilation
- Obesity Hypoventilation Syndrome
Other Study ID Numbers
Other Study ID Numbers
- CIA-156
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.